Novel anti-inflammatory strategies in atherosclerosis

Current Opinion in Lipidology

Volumn 23, Issue 6, 2012, Pages 532-539

  Van Der Valk, Fleur M ^a   Van Wijk, Diederik F ^a   Stroes, Erik S G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

anti inflammatory strategies; atherosclerosis; cardiovascular imaging; vessel wall inflammation

Indexed keywords

ADALIMUMAB; ATRELEUTON; C REACTIVE PROTEIN; CANAKINUMAB; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; DARAPLADIB; FIBRINOGEN; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; MLN 1202; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; UNCLASSIFIED DRUG; VARESPLADIB; VASCULAR CELL ADHESION MOLECULE 1; VELIFLAPON;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CELL ADHESION; CELL MIGRATION; DISEASE COURSE; DOSE RESPONSE; HEART INFARCTION; HUMAN; INFLAMMATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BLOOD VESSELS; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY;

EID: 84870004060     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283587543     Document Type: Review

References (92)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473:317-325. This is a detailed review on the inflammatory hypothesis of atherogenesis and the need for extrapolation to humans.
3. Swirski FK, Nahrendorf M, Libby P. The ins and outs of inflammatory cells in atheromata. Cell Metab 2012; 15:135-136.
4. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107:1255-1262. (Pubitemid 32494542)
5. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2:275-281. (Pubitemid 128373654)
6. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2/mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394:894-897. (Pubitemid 28410911)
7. Peters W, Charo IF. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol 2001; 12:175-180. (Pubitemid 32242925)
8. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150:1687-1699. (Pubitemid 27193816)
9. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13:587-596. (Pubitemid 46828480)
10. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003; 91:3A-6.A. (Pubitemid 36351456)
11. Gilstrap LG, Wang TJ. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 2012; 58:72-82.
12. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
13. Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006; 113:38-43. (Pubitemid 43958486)
14. Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. Br Med J 2011; 342:d548.
15. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5:600-610.
16. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772. (Pubitemid 30213096)
17. Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379:1205-1213. This study provides solid evidence for a causal role of the pro-inflammatory IL-6 pathway in determining risk of coronary heart disease.
18. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012; 379:1214-1224. This article provides strong grounds for IL6R to have a causal role in development of coronary heart disease.
19. Gurevich VS, Pleskov VM, Levaya MV. Autoimmune nature of influenza atherogenicity. Ann N Y Acad Sci 2005; 1050:410-416. (Pubitemid 41129460)
20. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351:2611-2618. (Pubitemid 39628582)
21. van Leuven SI, Kastelein JJ, D'Cruz DP, et al. Atherogenesis in rheumatology. Lupus 2006; 15:117-121.
22. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108:2957-2963. (Pubitemid 37553561)
23. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24:445-451. (Pubitemid 27153406)
24. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52:402-411. (Pubitemid 40220344)
25. van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, et al. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(/) mice. Ann Rheum Dis 2012; 71:408-414.
26. Li L, Messas E, Batista EL Jr., et al. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 2002; 105:861-867. (Pubitemid 34174928)
27. Westerterp M, Berbee JF, Pires NM, et al. Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 2007; 116:2173-2181. (Pubitemid 350060355)
28. Alber DG, Powell KL, Vallance P, et al. Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation 2000; 102:779-785. (Pubitemid 30648767)
29. van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8:R151.
30. Micha R, Imamura F, Wyler von BM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108:1362-1370.
31. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79:360-376.
32. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 2011; 31:1506-1516.
33. Hansson GK, Libby P. The immune response in atherosclerosis: a doubleedged sword. Nat Rev Immunol 2006; 6:508-519. (Pubitemid 43980523)
34. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109 (23 SUPPL. 1):III39-III43. (Pubitemid 38786442)
35. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103:276-283. (Pubitemid 32095415)
36. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, et al. Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Life Sci 2004; 75:1287-1302. (Pubitemid 38845028)
37. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline highsensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 2010; 106:204-209.
38. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015-2021. (Pubitemid 38781100)
39. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46:1855-1862. (Pubitemid 41579807)
40. Barter PJ, Rye KA. Cholesteryl ester transfer protein (CETP) inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 2012; 53:1755-1766.
41. Birjmohun RS, van Leuven SI, Levels JH, et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 2007; 27:1153-1158. (Pubitemid 46641971)
42. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel noninvasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378:1547-1559.
43. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. (Pubitemid 350146106)
44. Tardif JC, Gregoire J, L'allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 2007; 297:1675-1682. (Pubitemid 46631626)
45. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71 (SUPPL. 2):i2-i45.
46. van Leuven SI, van Wijk DF, Volger OL, et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 2010; 211:231-236.
47. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177. (Pubitemid 34304256)
48. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7 (SUPPL. 1):332-339.
49. Karampetsou MP, Liossis SN, Sfikakis PP. TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010; 103:917-928.
50. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133-3140. (Pubitemid 36793081)
51. Riminton DS, Hartung HP, Reddel SW. Managing the risks of immunosuppression. Curr Opin Neurol 2011; 24:217-223.
52. Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 2006; 113:2936-2942. (Pubitemid 44297235)
53. Owen DR, Lindsay AC, Choudhury RP, Fayad ZA. Imaging of atherosclerosis. Annu Rev Med 2011; 62:25-40.
54. Camici PG, Rimoldi OE, Gaemperli O, Libby P. Noninvasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J 2012; 33:1309-1317.
55. Duivenvoorden R, de GE, Afzali H, et al. Comparison of in vivo carotid 3.0-T magnetic resonance to B-mode ultrasound imaging and histology in a porcine model. JACC Cardiovasc Imaging 2009; 2:744-750.
56. Duivenvoorden R, de GE, Elsen BM, et al. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ Cardiovasc Imaging 2009; 2:235-242.
57. Li F, Yarnykh VL, Hatsukami TS, et al. Scan-rescan reproducibility of carotid atherosclerotic plaque morphology and tissue composition measurements using multicontrast MRI at 3T. J Magn Reson Imaging 2010; 31:168-176.
58. Calcagno C, Mani V, Ramachandran S, Fayad ZA. Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis. Angiogenesis 2010; 13:87-99.
59. Takaya N, Cai J, Ferguson MS, et al. Intra-and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J Magn Reson Imaging 2006; 24:203-210.
60. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol 1995; 26:450-456.
61. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008; 49:871-878. (Pubitemid 351793426)
62. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48:1818-1824. (Pubitemid 44648622)
63. Pedersen SF, Graebe M, Fisker Hag AM, et al. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun 2010; 31:423-429.
64. Marnane M, Merwick A, Sheehan OC, et al. Carotid plaque inflammation on (18) F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol 2012; 71:709-718.
65. Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 2008; 7:517-529. (Pubitemid 351767119)
66. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504. (Pubitemid 38477774)
67. Abbate A, Van Tassell BW, Biondi-Zoccai GG. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs 2012; 26:217-233.
68. Galea J, Armstrong J, Gadsdon P, et al. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 1996; 16:1000-1006. (Pubitemid 26266899)
69. Kastrati A, Koch W, Berger PB, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000; 36:2168-2173.
70. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162:597-605.
71. Crossman DC, Morton AC, Gunn JP, et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 2008; 9:8.
72. Yabe Y, Kojima T, Kaneko A, et al. A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study. Mod Rheumatol 2012 [Epub ahead of print].
73. Boekholdt SM, Stroes ES. The interleukin-6 pathway and atherosclerosis. Lancet 2012; 379:1176-1178.
74. Gilbert J, Lekstrom-Himes J, Donaldson D, et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol 2011; 107:906-911.
75. Corson MA. Phospholipase A2 inhibitors in atherosclerosis: the race is on. Lancet 2009; 373:608-610.
76. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-1544.
77. Mallat Z, Steg PG, Benessiano J, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005; 46:1249-1257. (Pubitemid 41615545)
78. Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009; 373:649-658.
79. Nicholls SJ, Cavender MA, Kastelein JJ, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther 2012; 26:71-75.
80. Anthera Pharmaceuticals. http://investor.anthera.com/releases.cfm. 2012.
81. Mohler ER III, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008; 51:1632-1641. (Pubitemid 351635837)
82. Vedin O, Hagstrom E, Stewart R, et al. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. Eur J Prev Cardiol 2012 [Epub ahead of print].
83. O'Donoghue ML, Braunwald E, White HD, et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 2011; 162:613-619.
84. Funk CD. Leukotriene inflammatory mediators meet their match. Sci Transl Med 2011; 3:article 66ps3.
85. Tardif JC, L'allier PL, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010; 3:298-307.
86. Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. J Am Med Assoc 2005; 293:2245-2256. (Pubitemid 40629191)
87. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 2011; 10:835-852. This is an excellent review on recent advantages in nanomedicine in atherosclerosis.
88. Jung SH, Lim DH, Jung SH, et al. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur J Pharm Sci 2009; 37:313-320.
89. Barenholz YC. Doxil(R): the first FDA-approved nano-drug: lessons learned. J Control Release 2012; 160:117-134.
90. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, et al. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003; 48:2059-2066. (Pubitemid 36828702)
91. Dams ET, Nijhof MW, Boerman OC, et al. Scintigraphic evaluation of experimental chronic osteomyelitis. J Nucl Med 2000; 41:896-902. (Pubitemid 30266036)
92. Stroes ESG. Silencing inflammatory activity by injecting nanocort in patients at risk for atherosclerotic disease (SILENCE). ClinicalTrials gov Identifier: NCT01601106 2012.